Search

Your search keyword '"Okada, Annabelle A."' showing total 17 results
Start Over Author "Okada, Annabelle A." Journal american journal of ophthalmology
17 results on '"Okada, Annabelle A."'

3. Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease

Author

Read, Russell W., Yu, Fei, Accorinti, Massimo, Bodaghi, Bahram, Chee, Soon-Phaik, Fardeau, Christine, Goto, Hiroshi, Holland, Gary N., Kawashima, Hidetoshi, Kojima, Eri, LeHoang, Phuc, Lemaitre, Claire, Okada, Annabelle A., Pivetti-Pezzi, Paola, Secchi, Antonio, See, Robert F., Tabbara, Khalid F., Usui, Masahiko, and Rao, Narsing A.

Published
2006
Full Text
View/download PDF

4. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab

Author

Storey, Philip P., primary, Tauqeer, Zujaja, additional, Yonekawa, Yoshihiro, additional, Todorich, Bozho, additional, Wolfe, Jeremy D., additional, Shah, Sumit P., additional, Shah, Ankoor R., additional, Koto, Takashi, additional, Abbey, Ashkan M., additional, Morizane, Yuki, additional, Sharma, Priya, additional, Wood, Edward H., additional, Morizane-Hosokawa, Mio, additional, Pendri, Pooja, additional, Pancholy, Maitri, additional, Harkey, Shawn, additional, Jeng-Miller, Karen W., additional, Obeid, Anthony, additional, Borkar, Durga S., additional, Chen, Eric, additional, Williams, Patrick, additional, Okada, Annabelle A., additional, Inoue, Makoto, additional, Shiraga, Fumio, additional, Hirakata, Akito, additional, Shah, Chirag P., additional, Prenner, Jonathan, additional, and Garg, Sunir, additional

Published
2019
Full Text
View/download PDF

5. Interobserver Agreement Among Uveitis Experts on Uveitic Diagnoses: The Standardization of Uveitis Nomenclature Experience

Author

Jabs, Douglas A., primary, Dick, Andrew, additional, Doucette, John T., additional, Gupta, Amod, additional, Lightman, Susan, additional, McCluskey, Peter, additional, Okada, Annabelle A., additional, Palestine, Alan G., additional, Rosenbaum, James T., additional, Saleem, Sophia M., additional, Thorne, Jennifer, additional, and Trusko, Brett, additional

Published
2018
Full Text
View/download PDF

6. Reply

Author

Koizumi, Hideki, primary, Yamamoto, Akiko, additional, Maruko, Ichiro, additional, Okada, Annabelle A., additional, Iida, Tomohiro, additional, Kano, Mariko, additional, Saito, Masaaki, additional, Sekiryu, Tetsuju, additional, and Kawasaki, Ryo, additional

Published
2016
Full Text
View/download PDF

7. Reply

Author

Koizumi, Hideki, primary, Yamamoto, Akiko, additional, Maruko, Ichiro, additional, Okada, Annabelle A., additional, Iida, Tomohiro, additional, Kano, Mariko, additional, Saito, Masaaki, additional, Sekiryu, Tetsuju, additional, and Kawasaki, Ryo, additional

Published
2015
Full Text
View/download PDF

14. Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration.

Author

HIDEKI KOIZUMI, MARIKO KANO, AKIKO YAMAMOTO, MASAAKI SAITO, ICHIRO MARUKO, RYO KAWASAKI, TETSUJU SEKIRYU, OKADA, ANNABELLE A., and IIDA, TOMOHIRO

Subjects
*RETINAL degeneration, *RETINAL degeneration treatment, *CHOROID, *NEOVASCULARIZATION, *OPTICAL coherence tomography, *RETROSPECTIVE studies, *DIAGNOSIS
Abstract

PURPOSE: To investigate changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration (AMD). DESIGN: Retrospective, consecutive, interventional case series. METHODS: This study included 102 eyes of 102 patients with treatment-naive neovascular AMD. All 102 eyes underwent 3 consecutive monthly 2.0 mg intravitreal aflibercept injections at baseline, 1 month, and 2 months. Choroidal thickness during 3 months were evaluated using either swept-source optical coherence tomography (OCT) or enhanced-depth imaging OCT. RESULTS: Of the 102 eyes, 46 eyes (45.1%) were diagnosed as typical neovascular AMD and 56 eyes (54.9%) as polypoidal choroidal vasculopathy. After intravitreal aflibercept injections, the mean subfoveal choroidal thickness decreased from 252.0 ± 99.7 µm at baseline to 217.9 ± 95.6 µm at 3 months (P < .0001; percentage change from baseline, 86.5%). Mean choroidal thickness measured at 3 µm from the foveal center in the superior, inferior, temporal, and nasal directions also decreased significantly from 258.7 ± 85.9 µm to 236.4 ± 84.6 µm, 229.9 ± 93.0 µm to 208.6 ± 86.5 µm, 237.4 ± 86.5 µm to 214.6 ± 79.5 µm, and 183.7 ± 97.0 µm to 162.3 ± 90.6 µm, respectively (P < .0001 for all directions). Both subtypes of neovascular AMD demonstrated a similar trend toward decreasing choroidal thickness during the follow-up period. CONCLUSIONS: Choroidal thickness significantly decreased not only at the foveal center but also in the entire macula after 3 monthly intravitreal aflibercept injections for neovascular AMD. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

17. Reply: To PMID 25555799.

Author

Koizumi H, Yamamoto A, Maruko I, Okada AA, Iida T, Kano M, Saito M, Sekiryu T, and Kawasaki R

Subjects
Female, Humans, Male, Angiogenesis Inhibitors therapeutic use, Choroid drug effects, Choroid pathology, Receptors, Vascular Endothelial Growth Factor therapeutic use, Recombinant Fusion Proteins therapeutic use, Wet Macular Degeneration drug therapy
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results